P2Y purinoceptor 12 and P2Y purinoceptor 1 (P2Y12 and P2Y1)

Platelet ADP receptors, specifically the P2Y1 and P2Y12 subtypes, are essential components of the ADP-induced aggregation pathway, which is critical for physiological hemostasis and the development of pathological arterial thrombosis (Gachet, 2001). The P2Y1 receptor is a Gq-coupled protein that initiates platelet shape change and the initial phase of aggregation by mobilizing intracellular calcium stores (StatPearls, 2023). In contrast, the P2Y12 receptor is a Gi-coupled protein that inhibits adenylyl cyclase, leading to a decrease in cAMP levels, which is necessary for the stabilization of platelet aggregates and the full aggregation response (NIH, 2026). This pathway is a primary target for antiplatelet therapy in patients with cardiovascular diseases, such as acute coronary syndrome and those undergoing percutaneous coronary intervention (AHA Journals, 2000). Drugs like clopidogrel, prasugrel, and ticagrelor act as P2Y12 antagonists, effectively reducing the risk of major adverse cardiovascular events by preventing thrombus formation (MDPI, 2021). However, the clinical use of these agents is balanced against the risk of bleeding and is influenced by genetic factors, such as CYP2C19 polymorphisms, that affect drug metabolism (PubMed, 2015). Monitoring of platelet function and genetic testing can help optimize therapy and minimize adverse effects in high-risk patients (NIH, 2026).

Other names

Platelet ADP receptors and ADP-induced aggregation pathwayP2Y purinoceptor 12P2Y purinoceptor 1P2Y12 receptorP2Y1 receptorP2RY12P2RY1P2TP2YacSP1999ADP receptor

Antagonism of the P2Y12 receptor (irreversible for thienopyridines like clopidogrel and prasugrel; reversible for ticagrelor and cangrelor) to inhibit ADP-induced platelet aggregation and thrombus stabilization.